Bristol Myers Squibb Reports First Phase 3 Clinical Results from ADEPT Program Evaluating KarXT for Alzheimer’s Disease-Related Psychosis

Bristol Myers Squibb Reports Preliminary Phase 3 ADEPT Study Results Showing Improvements in Alzheimer’s Disease-Related Psychosis With KarXT

Bristol Myers Squibb, a global biopharmaceutical company focused on developing innovative medicines for serious diseases, has announced preliminary Phase 3 clinical findings evaluating the short- and long-term treatment effects of xanomeline and trospium chloride (KarXT) in patients experiencing psychosis associated with Alzheimer’s disease. The findings come from the 12-week open-label treatment period of the ADEPT-1 study and the 52-week open-label extension (OLE) ADEPT-3 study.

According to the company, treatment with KarXT was associated with improvements in clinician-observed measures of hallucinations, delusions and overall disease severity across both clinical studies. The treatment was also generally well tolerated during the evaluated treatment periods, with no new safety signals identified.

The preliminary findings represent the first clinical data disclosure from Bristol Myers Squibb’s Phase 3 ADEPT clinical development program investigating KarXT for psychosis associated with Alzheimer’s disease. The results were presented in an oral presentation, Abstract #OC21, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, Massachusetts.

The ADEPT clinical program is designed to evaluate the potential role of KarXT in addressing psychosis symptoms among people living with Alzheimer’s disease. The program includes studies assessing treatment response, safety and tolerability, with the objective of generating clinical evidence for a condition that can create substantial challenges for patients, families and caregivers.

Importantly, the ADEPT trials remain ongoing, and results from the double-blind treatment periods across all studies in the program remain blinded. The findings currently reported are based on descriptive analyses of participants who completed or prematurely discontinued the respective open-label treatment periods. Participants who were still receiving treatment at the time of the data cutoff were excluded from the analysis.

Addressing Psychosis Associated With Alzheimer’s Disease

Alzheimer’s disease is a progressive neurological condition that affects memory, thinking, behavior and the ability to perform everyday activities. Although cognitive impairment is a defining feature of the disease, many patients also experience behavioral and psychological symptoms that can significantly affect their quality of life.

Psychosis associated with Alzheimer’s disease can involve hallucinations and delusions. Hallucinations may cause individuals to perceive things that are not present, while delusions involve strongly held false beliefs that can influence how patients interpret their surroundings and interact with others.

These symptoms can be particularly distressing and may contribute to increased dependence on caregivers, difficulties with daily activities and additional challenges in managing the disease. Families and healthcare professionals often face significant difficulties when attempting to manage these symptoms alongside the cognitive and functional effects of Alzheimer’s disease.

Despite the considerable burden associated with Alzheimer’s-related psychosis, treatment options remain limited. Consequently, there is an ongoing need for therapeutic approaches that can help address these symptoms while maintaining an acceptable safety and tolerability profile.

KarXT, a combination of xanomeline and trospium chloride, is being investigated by Bristol Myers Squibb as a potential treatment approach for psychosis associated with Alzheimer’s disease. The Phase 3 ADEPT program is evaluating its effects over different treatment durations to better understand both initial clinical responses and longer-term treatment characteristics.

ADEPT-1 Study: Preliminary Findings From 12-Week Open-Label Treatment

The ADEPT-1 study includes a 12-week open-label lead-in period designed to evaluate the effects of KarXT treatment in patients with psychosis associated with Alzheimer’s disease.

At the time of the preliminary analysis, 320 participants had been enrolled in the study. Of these participants, 273, representing 85.3% of the enrolled population, completed the 12-week open-label treatment period.

During the treatment period, participants receiving KarXT demonstrated improvements from baseline in clinician-observed hallucination and delusion scores, as well as overall disease severity.

The primary symptom assessment highlighted in the preliminary findings was the Neuropsychiatric Inventory-Clinician Hallucinations and Delusions (NPI-C H+D) scale. This measure evaluates the severity of hallucinations and delusions based on clinician assessments and provides an indication of changes in these neuropsychiatric symptoms during treatment.

Among the participants included in the analysis, KarXT treatment was associated with a mean reduction of 12.0 points on the NPI-C H+D scale from a baseline score of 14.4. The analysis included 266 participants.

The reduction indicates an improvement in clinician-observed hallucination and delusion symptoms during the 12-week treatment period.

Researchers also evaluated overall disease severity using the Clinical Global Impression-Severity (CGI-S) scale. This clinical assessment provides an overall measure of a patient’s illness severity based on the clinician’s evaluation.

Among 267 participants assessed, the mean CGI-S score decreased by 1.9 points from a baseline of 4.5 following 12 weeks of treatment with KarXT.

These preliminary findings suggest improvements across both symptom-specific and overall disease severity assessments during the open-label period.

Safety and Tolerability in ADEPT-1

In addition to evaluating clinical responses, the ADEPT-1 study assessed the safety and tolerability of KarXT during the 12-week treatment period.

Treatment-emergent adverse events (TEAEs) were reported in 56.6% of participants. Serious treatment-emergent adverse events occurred in 5.0% of participants, while adverse events leading to treatment discontinuation were reported in 4.4%.

The relatively low proportion of participants discontinuing treatment because of adverse events provides an additional component of the preliminary tolerability assessment.

Bristol Myers Squibb reported that KarXT was generally well tolerated during the open-label treatment period. The company also noted that no new safety signals were identified in the preliminary findings.

However, the safety observations remain part of an ongoing clinical development program, and additional data from the controlled treatment periods will be important for establishing a more comprehensive understanding of the medicine’s safety profile.

ADEPT-3 Study: Evaluating Long-Term Safety and Treatment Outcomes Over 52 Weeks

While ADEPT-1 provides an initial assessment of treatment response over 12 weeks, the ADEPT-3 study is designed to investigate the longer-term safety and tolerability of KarXT.

ADEPT-3 is an open-label extension study for patients who complete the double-blind treatment periods of the ADEPT-1, ADEPT-2 or ADEPT-4 studies. The study provides an opportunity to evaluate continued treatment over an extended period and examine whether improvements in clinical measures are observed during longer-term exposure.

At the time of the preliminary analysis, 401 participants had enrolled in ADEPT-3. Of these, 273 participants, representing 68.1% of the enrolled population, completed the 52-week treatment period.

The preliminary results showed that KarXT was generally well tolerated through Week 52, with relatively low rates of treatment discontinuation.

Treatment-emergent adverse events were reported in 65.1% of participants. Serious TEAEs occurred in 7.7% of participants, while TEAEs leading to treatment discontinuation were reported in 4.7%.

These findings provide preliminary information about the tolerability of KarXT during extended treatment in patients with Alzheimer’s disease-related psychosis.

Improvements in Hallucinations, Delusions and Disease Severity

In addition to long-term safety assessments, the ADEPT-3 study evaluated changes in hallucination and delusion symptoms and overall disease severity during the 52-week open-label extension.

The NPI-C H+D scale demonstrated a mean reduction of 5.1 points from an open-label baseline score of 8.9. This analysis included 270 participants.

The findings indicate improvements in clinician-observed hallucination and delusion symptoms during the evaluated long-term treatment period.

The CGI-S assessment also demonstrated a mean reduction of 0.8 points from an open-label baseline score of 3.4 among 277 participants.

Together, these results suggest that improvements in symptom-related and overall disease severity measures were observed during the longer-term treatment period.

The ADEPT-3 findings are particularly relevant because long-term treatment is an important consideration when evaluating potential therapies for chronic neurological conditions such as Alzheimer’s disease.

Although the results are preliminary and based on descriptive analyses, they provide additional information about the treatment experience of patients receiving KarXT over an extended period.

Experts Highlight the Potential Importance of the Findings

Jeffrey L. Cummings, MD, ScD, Joy Chambers-Grundy professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience in the Kirk Kerkorian School of Medicine at UNLV, emphasized the significant impact of hallucinations and delusions on individuals living with Alzheimer’s disease and their families.

He noted that these symptoms represent particularly challenging aspects of the condition and can create an additional burden for patients, caregivers and family members.

According to Cummings, the preliminary ADEPT findings contribute to the understanding of KarXT’s potential impact in this treatment setting. He also highlighted the importance of exploring new therapeutic approaches that may help reduce the burden associated with psychosis in people living with Alzheimer’s disease.

His comments reflect the broader need for continued research into treatments that address not only cognitive symptoms but also the behavioral and psychological complications associated with Alzheimer’s disease.

Cristian Massacesi, MD, executive vice president, chief medical officer and head of development at Bristol Myers Squibb, also highlighted the company’s commitment to advancing innovative science for individuals living with complex neurological and psychiatric conditions.

Massacesi explained that ADEPT-1 and ADEPT-3 are designed to address two different but complementary clinical questions.

The 12-week open-label treatment period in ADEPT-1 provides an initial assessment of how patients respond to KarXT over a relatively short treatment duration. In contrast, ADEPT-3 is focused on evaluating the long-term safety and tolerability of the treatment over 52 weeks.

He stated that the improvements in hallucination and delusion scores observed in ADEPT-1, together with the long-term safety and tolerability findings from ADEPT-3, are encouraging as the company awaits additional results from the double-blind periods of the ADEPT program.

Bristol Myers Squibb intends to share further clinical findings as the studies progress and additional data become available.

Importance of the Ongoing Phase 3 ADEPT Program

The preliminary findings represent an important development in the clinical evaluation of KarXT for Alzheimer’s disease-related psychosis. By examining both short-term treatment responses and longer-term safety outcomes, the ADEPT program aims to build a more comprehensive understanding of the medicine’s potential role in managing these symptoms.

The distinction between the two studies is important. ADEPT-1 provides preliminary information about changes in hallucinations, delusions and overall disease severity during the initial 12-week period. ADEPT-3 extends the evaluation to 52 weeks, offering additional information about tolerability and symptom measures during prolonged treatment.

Nevertheless, the current findings should be interpreted within the limitations of their study designs. The reported analyses are descriptive, and the open-label periods do not provide the same level of controlled comparative evidence as randomized, double-blind treatment periods.

The double-blind portions of the ADEPT studies remain ongoing, with their results still blinded. Future findings from these controlled periods will be important for evaluating the treatment’s efficacy and establishing its potential clinical benefits more conclusively.

Bristol Myers Squibb Continues Its Focus on Neurological and Psychiatric Conditions

Bristol Myers Squibb continues to advance its research and development activities across complex diseases, including neurological and psychiatric conditions where significant unmet medical needs remain.

The company’s investigation of KarXT in Alzheimer’s disease-related psychosis reflects its efforts to explore additional treatment approaches for patients experiencing challenging behavioral and psychological symptoms.

The ADEPT program is supported by the participation of patients, clinical investigators and research sites. Bristol Myers Squibb expressed its appreciation to everyone involved in the studies and acknowledged their contributions to advancing clinical research in Alzheimer’s disease.

Patients, families and healthcare professionals seeking additional information about the clinical trials, including eligibility requirements and participation opportunities, can visit NavigatingALZ.com.

As the Phase 3 ADEPT program continues, additional clinical data will help clarify the potential of xanomeline and trospium chloride as a treatment option for psychosis associated with Alzheimer’s disease. The preliminary 12-week and 52-week findings provide an initial look at symptom improvements and long-term tolerability, while results from the ongoing double-blind treatment periods remain an important next milestone in the program.

About the ADEPT Program
The ADEPT-1 clinical trial (clinicaltrials.gov, NCT05511363) is a global, Phase 3, randomized, double-blind, placebo-controlled relapse prevention study to evaluate the safety and efficacy of xanomeline and trospium chloride (KarXT) in adults with psychosis associated with Alzheimer’s disease. The study includes a 12-week open-label treatment period preceding a 26-week, double-blind, randomized withdrawal period. The study is designed to evaluate the primary endpoint of time to relapse event during the 26-week double-blind period.

The ADEPT-3 clinical trial (clinicaltrials.gov, NCT05980949) is a Phase 3 global, 52-week, open-label extension (OLE) rollover study for participants completing the ADEPT-1, ADEPT-2 or ADEPT-4 studies. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in adults with psychosis associated with Alzheimer’s disease.

The broader ADEPT program includes Phase 3 trials evaluating the acute efficacy of KarXT (ADEPT-2, NCT06126224; ADEPT-4, NCT06585787) and a study evaluating twice-daily (BID) dosing (ADEPT-5, NCT06947941).

About Psychosis Associated with Alzheimer’s Disease
Alzheimer’s disease is a progressive, multifaceted and devastating neurodegenerative disease and is the most common type of dementia in adults. Changes in the brain disrupt communication between neurons, impacting memory, cognition and behavior.

Approximately 30-50% of patients with Alzheimer’s disease experience symptoms such as hallucinations and delusions, called psychosis, over the course of the disease. Hallucinations (seeing or hearing things that aren’t there) and delusions (believing something that is untrue) are linked to faster cognitive and functional decline, greater caregiver burden, higher rates of institutionalization and mortality, and are often among the most distressing aspects of the disease for patients and their families. Despite the significant impact these symptoms can have, there are currently no FDA-approved treatments specifically for psychosis associated with Alzheimer’s disease. Management typically relies on off‑label use of antipsychotics, which can be associated with important safety concerns in older adults with dementia.

About KarXT
KarXT (xanomeline and trospium chloride) is an investigational oral medication in development for neurologic indications where significant gaps in care remain, including Alzheimer’s disease-associated cognitive impairment, psychosis and agitation; acute mania or mania with mixed features in bipolar I disorder and autism-associated irritability.

KarXT combines xanomeline, a dual M1– and M4-preferring muscarinic receptor agonist, with trospium chloride, a muscarinic receptor antagonist designed to reduce peripheral cholinergic side effects. Through central cholinergic muscarinic receptor modulation, KarXT is designed to engage molecular pathways involved in behavior and cognition.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter